Oyster Venture Partners is supporting a client in the mobile health sector seeking to complete a Series A investment round. Please find below our detailed summary of the Gendius investment opportunity and fund-raising programme.
Investment Profile
Investment Profile
Our mission is that every person with diabetes understands their risk of
developing complications & how to manage them.
Our mission is that every person with diabetes understands their risk of developing complications & how to manage them.
Valuation:
£20m pre-money
Investment Sought:
£5.8m for 19.1% equity
(Q3 2020)
For further details click here to register your interest
For further details click here to register your interest
Investment Summary
Investment Summary
- Contract with AstraZeneca to use intellin across the Gulf States (Middle East).
- Contracts with several NHS Clinical Commissioning Groups (CCGs).
- 200,000+ downloads. 170+ countries.
- Growing at 10,000+ per week, with high rate of retention.
- Top 16% of all-time mHealth apps.
- Unique AI platform solution.
- Connected to 150+ devices.
The Diabetes Market
- 10% of the global population have diabetes ($760bn)
- 11.6% of the global spend on health is on diabetes.
- Diabetes is the number 1 cause of blindness, kidney failure, lower limb amputation and increases your risk of having a heart attack or stroke by a factor of 2.5x.
- Every 7 seconds someone dies from diabetes or its complications
How Intellin® works
How Intellin® works
- Gendius is an innovative mobile health company that has developed Intellin®, a remote management platform for people with diabetes and their healthcare teams.
- Intellin® predicts the risk of complications of diabetes by using clinical data and applying algorithms to calculate an individuals risk of developing complications from diabetes.
- Advice is then pushed to the user recommending actions that may mitigate the risk of disease progression. The predictive capability is unique in the market.
Intellin® is the ‘sat nav’ remote management platform that provides a personalised prediction of future complications.
Intellin® is the ‘sat nav’ remote management platform that provides a personalised prediction of future complications.
Company
Gendius Limited
Alderley Park, Cheshire, UK
Traction
- Intellin® has been downloaded over 200,000 times in more than 170 Countries.
- Intellin® is being used across 5 NHS regions.
- Contract with AstraZeneca to integrate Intellin® into their existing educational platform. Initially for the Gulf states across 1,000 GP practices, with the plan to scale across the Middle East and into their other 8 innovation hubs.
Intellin® is connected to over 150 different apps and medical/wellness devices such as blood glucose monitors, blood pressure cuffs and continuous glucose monitors (CGM). This enables accurate, easy and class-leading remote monitoring, critical during COVID-19.
Valuation
£20m pre-money
Investment Sought
£5.8m for 19.1% equity (Q3 2020)
Use of Funds
- Supercharge commercialisation.
- Launch in the US & SE Asia.
- Further develop our AI capability and remote monitoring toolset.
- Translation into additional languages.
- Launch transitional care platform.
- Launch our gestational diabetes platform.
- Launch our adolescent platform.
Existing Investors
Founders
Catapult Ventures
Industry Venture Investors
HNWs and Crowdfunding
Leadership
Rory Cameron – CEO. 25yrs+ sales & marketing in pharma with digital heath exit track record.
Chris Genders – Co-founder. 30yrs+ in healthcare, pharma, digital heath and diabetes.
Albert Nicholl – Chairman. 30yrs+ in MedTech sector.
Iain Bailey – Lead Developer. 20yrs+ building & managing tech teams.
Dr Natasha Patel – EMBA from Imperial. Dedicated diabetologist.
Forward Investment Strategy
£6m 2020 as above
£10m 2022 to support a wider rollout programme and product extensions.
Exit in 2025.
Key Contacts
Rupert Lewis
CEO
Oyster Venture Partners
M: +44 (0)7860 640444
E: rupert.lewis@oystervp.com
Rory Cameron
CEO & Co-Founder
Gendius Ltd, Manchester, UK
M: +44 (0)7496 896782
E: roryc@gendius.co.uk
Click here to email Rupert
Click here to email Rory
The content of this communication has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this communication for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
Rupert Lewis
CEO
Oyster Venture Partners
M: +44 (0)7860 640444
E: rupert.lewis@oystervp.com
Click here to email Rupert
Rory Cameron
CEO & Co-Founder
Gendius Ltd, Manchester, UK
M: +44 (0)7496 896782
E: roryc@gendius.co.uk
Click here to email Rory
The content of this communication has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this communication for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
To register your interest, please complete the form below and click submit or contact Rupert Lewis per the email address above.